Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

NCT00591851 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]